Eli Lilly and Company (LLY)
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company NYSE: LLY went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the stock rose 41%.
Eli Lilly (LLY) Laps the Stock Market: Here's Why
Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.64% move from its prior day's close.
Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly
Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., in an effort to speed up the use of AI in the pharmaceutical industry. Denny Fish, portfolio manager on the Global Technology and Innovation Team at Janus Henderson Investors, joins Caroline Hyde and Ed Ludlow on “Bloomberg Tech.
Nvidia and Eli Lilly launch Co-Innovation AI Lab to advance drug discovery
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) and Eli Lilly and Co (NYSE:LLY) have announced the creation of a new AI-focused co-innovation lab aimed at accelerating drug discovery and development. The lab will combine Lilly's expertise in medicine discovery, development, and manufacturing with Nvidia's AI and computing capabilities, the companies announced on Monday.
Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma's Future
One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher.
2 non-tech stocks to hit $1 trillion market cap in 2026
For much of the past decade, trillion-dollar market capitalizations have been dominated by technology giants, driven by platform economics, artificial intelligence (AI), and cloud computing.
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software
Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.
Best Growth Stocks to Buy for January 8th
MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.
Eli Lilly's 2026 Resolution: Volume Is The New Price
Eli Lilly and Company remains a Buy, supported by robust incretin-driven growth and strategic expansion in obesity treatments. LLY pivots from scarcity to access economics, prioritizing volume over net price as orforglipron and ZEPBOUND expand reach. Retatrutide and oral pipeline assets, plus Nimbus and Superluminal deals, diversify revenue and mitigate single-asset risk.
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter
The more-than-$1 billion deal could come imminently.
